Characteristics of allotransplant subjects with PGF or GGF
| Characteristics . | PGF cases* (N = 26) . | GGF cases* (N = 26) . | P† . |
|---|---|---|---|
| BM evaluated time (post-HSCT days) | 60 (28-120) | 63(28-121) | 0.82 |
| Blood cell count | |||
| Median WBC (×109/L) (range) | 1.36 (1.02-2.36) | 4.15 (2.15-6.07) | <.0001 |
| Median ANC (×109/L) (range) | 0.35 (0.10-0.48) | 3.26 (1.24-4.50) | <.0001 |
| Median Hb (g/L) (range) | 55 (42-69) | 104 (75-130) | <.0001 |
| Median PLT (×109/L) (range) | 13 (8-19) | 118 (68-290) | <.0001 |
| Age at HSCT (years, median, range) | 41.5 (18-55) | 43 (18-56) | .82 |
| Sex (male/female) | 14/12 | 12/14 | .78 |
| Underlying disease | |||
| AML | 11 | 11 | 1.00 |
| ALL | 13 | 13 | 1.00 |
| MDS | 2 | 2 | 1.00 |
| Status at HSCT | 1.00 | ||
| Standard risk | 11 | 10 | |
| High risk | 15 | 16 | |
| Source of stem cell | 1.00 | ||
| BM and PB | 26 | 26 | |
| Transplanted total nucleated cell dose (×108/kg, median, range) | 7.10 (4.13-9.40) | 7.08 (3.60-9.35) | .80 |
| Transplanted CD34+ cell dose (×106/kg, median, range) | 2.50 (1.55-5.23) | 2.45 (1.25-5.18) | .86 |
| Donor match | 1.00 | ||
| HLA-identical sibling donor | 10 | 9 | |
| HLA–partially matched related donor | 16 | 17 | |
| Sex mismatch | |||
| Female to male | 4 | 4 | 1.00 |
| Female to female | 2 | 3 | 1.00 |
| Male to female | 10 | 11 | 1.00 |
| Male to male | 10 | 8 | .77 |
| ABO mismatch | |||
| No | 11 | 9 | .78 |
| Minor | 10 | 9 | 1.00 |
| Major | 5 | 8 | .52 |
| Pre-HSCT cycles of chemotherapy | 3 (0-6) | 4 (0-7) | .67 |
| Conditioning | 1.00 | ||
| BU/CY | 10 | 9 | |
| BU/CY+ATG | 16 | 17 | |
| Administration of rhG-CSF post-HSCT | 26 | 17 | .002 |
| History of GVHD | 14 | 16 | .78 |
| Onset of aGVHD (days, median, range) | 22 (18-55) | 20 (15-52) | .83 |
| History of CMV reactivation | 17 | 19 | .76 |
| Onset of CMV reactivation (days, median, range) | 30 (22-51) | 29 (21-48) | .85 |
| CMV reactivation treated with ganciclovir | 13 | 14 | 1.00 |
| Characteristics . | PGF cases* (N = 26) . | GGF cases* (N = 26) . | P† . |
|---|---|---|---|
| BM evaluated time (post-HSCT days) | 60 (28-120) | 63(28-121) | 0.82 |
| Blood cell count | |||
| Median WBC (×109/L) (range) | 1.36 (1.02-2.36) | 4.15 (2.15-6.07) | <.0001 |
| Median ANC (×109/L) (range) | 0.35 (0.10-0.48) | 3.26 (1.24-4.50) | <.0001 |
| Median Hb (g/L) (range) | 55 (42-69) | 104 (75-130) | <.0001 |
| Median PLT (×109/L) (range) | 13 (8-19) | 118 (68-290) | <.0001 |
| Age at HSCT (years, median, range) | 41.5 (18-55) | 43 (18-56) | .82 |
| Sex (male/female) | 14/12 | 12/14 | .78 |
| Underlying disease | |||
| AML | 11 | 11 | 1.00 |
| ALL | 13 | 13 | 1.00 |
| MDS | 2 | 2 | 1.00 |
| Status at HSCT | 1.00 | ||
| Standard risk | 11 | 10 | |
| High risk | 15 | 16 | |
| Source of stem cell | 1.00 | ||
| BM and PB | 26 | 26 | |
| Transplanted total nucleated cell dose (×108/kg, median, range) | 7.10 (4.13-9.40) | 7.08 (3.60-9.35) | .80 |
| Transplanted CD34+ cell dose (×106/kg, median, range) | 2.50 (1.55-5.23) | 2.45 (1.25-5.18) | .86 |
| Donor match | 1.00 | ||
| HLA-identical sibling donor | 10 | 9 | |
| HLA–partially matched related donor | 16 | 17 | |
| Sex mismatch | |||
| Female to male | 4 | 4 | 1.00 |
| Female to female | 2 | 3 | 1.00 |
| Male to female | 10 | 11 | 1.00 |
| Male to male | 10 | 8 | .77 |
| ABO mismatch | |||
| No | 11 | 9 | .78 |
| Minor | 10 | 9 | 1.00 |
| Major | 5 | 8 | .52 |
| Pre-HSCT cycles of chemotherapy | 3 (0-6) | 4 (0-7) | .67 |
| Conditioning | 1.00 | ||
| BU/CY | 10 | 9 | |
| BU/CY+ATG | 16 | 17 | |
| Administration of rhG-CSF post-HSCT | 26 | 17 | .002 |
| History of GVHD | 14 | 16 | .78 |
| Onset of aGVHD (days, median, range) | 22 (18-55) | 20 (15-52) | .83 |
| History of CMV reactivation | 17 | 19 | .76 |
| Onset of CMV reactivation (days, median, range) | 30 (22-51) | 29 (21-48) | .85 |
| CMV reactivation treated with ganciclovir | 13 | 14 | 1.00 |
ABO, ABO blood group; aGVHD, acute GVHD; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; ANC, absolute neutrophil count; ATG, antithymocyte globulin; BU/CY, busulfan and cyclophosphamide; Hb, hemoglobin; MDS, myelodysplastic syndrome; PB, peripheral blood; PLT, platelet; rhG-CSF, recombinant human granulocyte colony-stimulating factor; WBC, white blood cell.
Group matching criteria included age at HSCT (±1 y), pre-HSCT cycles of chemotherapy (±1 cycle), disease status at HSCT, and BM microenvironment evaluated time after HSCT (±5 d). For each case, 1 GGF control was randomly selected from the same cohort at which the PGF occurred (“risk-set sampling”).
The continuous variables were compared using the Mann-Whitney U test, and the differences in frequency between the 2 groups were compared using the χ2 test. The criterion for statistical significance was P < .05.